Yamirka Sánchez, Martha L Concepción, Yohan Amador, Angel Piriz, René Rabassa, Ariel Leyva, Odalys Arguelles, Lisett Leblanch, Sheyla Moret, Gilberto Rivero, Ana L Vasallo, Beatriz Martorell, Pedro P Guerra, Ana R Valls, Lisset Sánchez, Yaimarelis Saumell
BACKGROUND: Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. METHODS: A prospective, nonrandomized, uncontrolled, open-label, and multicenter clinical trial was conducted to evaluate the safety and effectiveness of nimotuzumab combined with gemcitabine as first-line treatment in unresectable locally advanced or metastatic pancreatic tumors in a real-world condition...
2023: BioMed Research International